SIA
SRPT icon

Sit Investment Associates’s Sarepta Therapeutics SRPT Stock Holding History

Sit Investment Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,872
Closed -$323K – 542
2025
Q2 		$323K Sell
18,872
-30,060
-61% -$1.28M 0.01% 436
2025
Q1 		$3.12M Buy
48,932
+4,542
+10% +$478K 0.07% 258
2024
Q4 		$5.4M Buy
44,390
+8,038
+22% +$985K 0.12% 195
2024
Q3 		$4.54M Buy
36,352
+1,967
+6% +$272K 0.1% 217
2024
Q2 		$5.43M Buy
34,385
+309
+0.9% +$39.7K 0.13% 192
2024
Q1 		$4.41M Buy
34,076
+41
+0.1% +$5.02K 0.1% 214
2023
Q4 		$3.28M Hold
34,035
– – 0.08% 250
2023
Q3 		$4.13M Sell
34,035
-275
-0.8% -$31.1K 0.11% 200
2023
Q2 		$3.93M Buy
34,310
+3,525
+11% +$455K 0.1% 217
2023
Q1 		$4.24M Sell
30,785
-8,705
-22% -$1.13M 0.12% 205
2022
Q4 		$5.12M Sell
39,490
-700
-2% -$81.1K 0.14% 180
2022
Q3 		$4.44M Sell
40,190
-800
-2% -$80.6K 0.13% 178
2022
Q2 		$3.07M Sell
40,990
-425
-1% -$31.3K 0.09% 227
2022
Q1 		$3.23M Buy
41,415
+225
+0.5% +$17.2K 0.09% 249
2021
Q4 		$3.71M Buy
41,190
+7,425
+22% +$635K 0.09% 248
2021
Q3 		$3.12M Buy
33,765
+6,875
+26% +$530K 0.08% 252
2021
Q2 		$2.09M Sell
26,890
-11,200
-29% -$849K 0.05% 294
2021
Q1 		$2.84M Hold
38,090
– – 0.07% 267
2020
Q4 		$6.49M Hold
38,090
– – 0.18% 176
2020
Q3 		$5.35M Hold
38,090
– – 0.16% 189
2020
Q2 		$6.11M Hold
38,090
– – 0.19% 148
2020
Q1 		$3.73M Buy
38,090
+15,000
+65% +$1.71M 0.14% 189
2019
Q4 		$2.98M Sell
23,090
-12,300
-35% -$1.24M 0.08% 245
2019
Q3 		$2.67M Buy
35,390
+7,025
+25% +$830K 0.08% 249
2019
Q2 		$4.31M Buy
28,365
+6,300
+29% +$766K 0.13% 179
2019
Q1 		$2.63M Buy
22,065
+6,575
+42% +$845K 0.08% 238
2018
Q4 		$1.69M Hold
15,490
– – 0.05% 285
2018
Q3 		$2.5M Sell
15,490
-3,525
-19% -$482K 0.06% 240
2018
Q2 		$2.51M Sell
19,015
-8,360
-31% -$788K 0.06% 261
2018
Q1 		$2.03M Hold
27,375
– – 0.05% 287
2017
Q4 		$1.52M Sell
27,375
-5,850
-18% -$310K 0.04% 326
2017
Q3 		$1.51M Buy
33,225
+11,825
+55% +$473K 0.04% 318
2017
Q2 		$721K Buy
+21,400
New +$697K 0.02% 386

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sit Investment Associates's SRPT Position: Q3 2025 in Review

Sit Investment Associates sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 18,872 shares — an estimated $323K sold.

Sit Investment Associates first reported a position in SRPT in Q2 2017 and held it in 33 quarters. The position peaked at $6.49M in Q4 2020. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Sit Investment Associates reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sit Investment Associates sold 18,872 Sarepta Therapeutics shares in Q3 2025, an estimated $323K.
  • Sit Investment Associates first reported a position in Sarepta Therapeutics in Q2 2017 and held it in 33 quarters.
  • Sit Investment Associates's Sarepta Therapeutics position peaked at $6.49M in Q4 2020.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Sit Investment Associates's 13F filing for Q3 2025, filed 13 Nov 2025.